News in brief - July 2014 (updated)

Other new launches, licence changes and updates relevant to general practice.

The new formulation of MabThera (rituximab) is given by subcutaneous injection into the abdominal wall over five minutes.
The new formulation of MabThera (rituximab) is given by subcutaneous injection into the abdominal wall over five minutes.
  • Halaven (eribulin) can now be used to treat locally advanced or metastatic breast cancer that has progressed after a single chemotherapy regimen.
  • Fomicyt (fosfomycin) is an intravenous antibiotic for the treatment of acute osteomyelitis, complicated UTI, nosocomial lower RTI, meningitis, and bacteraemia associated with these infections.
  • InVita D3 (colecalciferol) is a new oral vitamin D3 solution for use in osteoporosis and vitamin D deficiency.
  • Scopoderm (hyoscine hydrobromide) patches can now be bought without a prescription from pharmacies for the treatment of travel sickness. Each 1.5mg patch can be used for up to 72 hours.
  • Roche has launched a new subcutaneous formulation of MabThera (rituximab) indicated in adults with non-Hodgkin’s lymphoma. The new formulation is not approved for use in children or for the rheumatoid arthritis or polyangiitis indications.
  • The licensed indications of Gardasil (human papillomavirus vaccine) have been extended to include the prevention of premalignant anal lesions and anal cancer. 
  • The pneumococcal vaccine Pneumovax II has been renamed Pneumococcal Polysaccharide Vaccine Sanofi Pasteur MSD.

Follow MIMS on Twitter

Sign up for MIMS bulletins

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in